for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ascletis Pharma Inc

1672.HK

Latest Trade

2.87HKD

Change

0.02(+0.70%)

Volume

2,037,000

Today's Range

2.84

 - 

2.91

52 Week Range

2.63

 - 

6.50

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2.85
Open
2.85
Volume
2,037,000
3M AVG Volume
20.00
Today's High
2.91
Today's Low
2.84
52 Week High
6.50
52 Week Low
2.63
Shares Out (MIL)
1,100.66
Market Cap (MIL)
3,136.89
Forward P/E
-142.50
Dividend (Yield %)
--

Next Event

Ascletis Pharma Inc Annual Shareholders Meeting

Latest Developments

More

First Subject Dosed With Gannex's FXR Agonist ASC42 In U.S. Phase I Trial

Ascletis Pharma Says Unit Got Fast Track Designation From U.S. FDA

Ascletis Pharma Inc Says Gannex Got IND Approval From U.S. FDA To Conduct Clinical Trials For NASH Indication

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ascletis Pharma Inc

Ascletis Pharma Inc. is a China-based company principally engaged in the research and development of biological products. The Company is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).

Industry

Biotechnology & Drugs

Contact Info

+86.571.85389730

http://www.ascletis.com/

Executive Leadership

Jinzi Jason Wu

Executive Chairman of the Board, Chief Executive Officer

Handan He

Chief Scientific Officer

Judy Hejingdao Wu

Vice President, Executive Director

Yuemei Yan

Vice President of Sales

Yi Chen

Vice President

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

0.2K

2019

0.2K

2020(E)

0.2K
EPS (CNY)

2018

-0.009

2019

-0.091

2020(E)

-0.019
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.15
Price To Book (MRQ)
0.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.08
LT Debt To Equity (MRQ)
0.03
Return on Investment (TTM)
-2.98
Return on Equity (TTM)
-2.92

Latest News

Latest News

BRIEF-Ascletis Pharma Says Sagimet Biosciences Announced Positive Results Of ‍Phase 2 NASH Trial​

* SAGIMET BIOSCIENCES ANNOUNCED POSITIVE RESULTS ON ORAL, ONCE-DAILY NON-ALCOHOLIC STEATOHEPATITIS DRUG CANDIDATE TVB-2640

BRIEF-Ascletis Pharma Says Gets IND Approval From NMPA For Category 1 Drug ASC41 For Clinical Trials

* GETS IND APPROVAL FROM NMPA FOR CATEGORY 1 DRUG ASC41 FOR CLINICAL TRIALS

BRIEF-Ascletis Pharma Got IND Approval Of Asc09/Ritonavir Fixed-Dose Combination (Asc09f)

* GOT INVESTIGATIONAL NEW DRUG APPROVAL FROM NMPA FOR ASC09/RITONAVIR FIXED-DOSE COMBINATION (ASC09F) Source text for Eikon: Further company coverage:

BRIEF-Ascletis Pharma FY Gross Profit Falls 19.3%

* EXPECTS COVID-19 OUTBREAK TO HAVE LIMITED IMPACT ON BUSINESS

BRIEF-Ascletis Pharma Updates On Clinical Trial Of Ganovo & Ritonavir On Coronavirus Pneumonia

* UPDATES ON CLINICAL TRIAL OF GANOVO (DANOPREVIR) & RITONAVIR COMBINATION THERAPY ON NOVEL CORONAVIRUS PNEUMONIA

BRIEF-Ascletis Pharma Updates On Clinical Trial Of Oral Ganovo & Ritonavir Combination Therapy On Novel Coronavirus

* ASCLETIS PHARMA INC - UPDATES ON CLINICAL TRIAL OF ORAL GANOVO & RITONAVIR COMBINATION THERAPY ON NOVEL CORONAVIRUS PNEUMONIA

BRIEF-Ascletis Pharma Says Application For Category I Drug ASC41 Developed Accepted By NMPA Of PRC

* APPLICATION FOR CATEGORY I DRUG ASC41 DEVELOPED BY UNIT ACCEPTED BY NMPA OF PRC Source text for Eikon: Further company coverage:

BRIEF-Ascletis Pharma Syas Ritonavir Gets Approval From For Study On Treatment Of Novel Coronavirus Pneumonia

* RITONAVIR GETS APPROVAL FROM REGULATORY AUTHORITIES OF ZHEJIANG PROVINCE FOR STUDY ON TREATMENT OF NOVEL CORONAVIRUS PNEUMONIA Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up